Nature Communications

Author Correction: DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B

2026-02-06

Full text

DOI https://doi.org/10.1038/s41467-026-69394-0